.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Novartis
Deloitte
Covington
Express Scripts
US Army
Fuji
Accenture
UBS
Julphar

Generated: July 28, 2017

DrugPatentWatch Database Preview

APTIOM Drug Profile

« Back to Dashboard

What is the patent landscape for Aptiom, and what generic Aptiom alternatives are available?

Aptiom is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has seventy patent family members in thirty countries.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eslicarbazepine acetate profile page.

Summary for Tradename: APTIOM

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list37
Clinical Trials: see list3
Patent Applications: see list44
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:APTIOM at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-004Nov 8, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-004Nov 8, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: APTIOM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-002Nov 8, 2013► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013► Subscribe► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-004Nov 8, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: APTIOM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,288,532Asymmetric catalytic reduction of oxcarbazepine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: APTIOM

Country Document Number Estimated Expiration
Russian Federation2439060► Subscribe
Portugal103467► Subscribe
World Intellectual Property Organization (WIPO)2009054743► Subscribe
Denmark0751129► Subscribe
Russian Federation2546521► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.



Supplementary Protection Certificates for Tradename: APTIOM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040France► SubscribePRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421
0Finland► Subscribe
C027/2009Ireland► SubscribeSPC027/2009: 20091119, EXPIRES: 20210627
00406Netherlands► SubscribePRODUCT NAME: ESLICARBAZEPINE, DESGEWENST IN; REGISTRATION NO/DATE: EU/1/09/514/001-020 20090421
C/GB09/047United Kingdom► SubscribePRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Boehringer Ingelheim
Johnson and Johnson
Deloitte
Cerilliant
Cantor Fitzgerald
Teva
Dow
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot